MedTrace Logo

Sayana® Press Self-injection Study in Malawi

NCT02293694 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 735

Last updated 2017-09-18

No results posted yet for this study

Summary

The feasibility of Sayana Press self-injection and the potential for this practice to increase contraceptive continuation has never been assessed in family planning programs in low-resource settings. The Malawi Ministry of Health (MOH) and the United States Agency for International Development (USAID) Malawi Mission requested the Advancing Partners and Communities (APC) project to assess self-injection of Sayana Press to inform their decision-making for procurement of Sayana Press and distribution through the health system in Malawi.

Conditions

  • Contraception

Interventions

DRUG

Sayana Press

Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject

Sponsors & Collaborators

  • FHI 360

    lead OTHER

Principal Investigators

  • Holly Burke, Ph.D. · FHI 360

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-17
Primary Completion
2017-01-27
Completion
2017-08-30

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02293694 on ClinicalTrials.gov